Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $5.99, for a total value of $99,835.33. Following the completion of the sale, the insider owned 1,209,840 shares in the company, valued at $7,246,941.60. The trade was a 1.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, March 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.25, for a total value of $104,168.75.
• On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.45, for a total value of $124,169.15.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $6.04 on Friday. The firm has a market cap of $1.04 billion, a PE ratio of -603.40 and a beta of 0.77. Xeris Biopharma Holdings, Inc. has a 12 month low of $3.81 and a 12 month high of $10.08. The stock’s 50 day simple moving average is $6.33 and its two-hundred day simple moving average is $7.29. The company has a current ratio of 2.19, a quick ratio of 1.57 and a debt-to-equity ratio of 16.10.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The firm had revenue of $85.81 million during the quarter, compared to analyst estimates of $86.00 million. Analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on XERS shares. Barclays started coverage on shares of Xeris Biopharma in a research note on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock. Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a report on Monday, March 2nd. Finally, Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Hedge Funds Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its stake in Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after buying an additional 198,984 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Xeris Biopharma by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after buying an additional 3,594 shares during the last quarter. Millennium Management LLC increased its stake in Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after buying an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP acquired a new position in shares of Xeris Biopharma during the first quarter valued at approximately $170,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.